rs of inflammation in individuals with elevated levels of C-reactive protein (CRP) in their blood. Subject screening and blood work has begun this week. As the company stated in a February 28 release that announced IRB approval for this study, elevated CRP levels are reliable markers for underlying chronic inflammation that is present in a number of coronary and vascular diseases, and in auto-immune diseases such as thyroid disease, diabetes and arthritis. The company anticipates that successful validation of the study hypothesis will result in the development and distribution of a nutraceutical product, based on RCP-006, aimed at maintaining healthy CRP levels.
There is intense focus in the scientific community on the search to identify compounds that can significantly reduce CRP levels and the underlying inflammatory processes they signal. The study sites are in the Flint, Michigan area, as well as in another area of the state. The principal investigators at the Roskamp Institute, which is overseeing the study, anticipate that 200-300 subjects will fully complete the study over the course of the next months. The Roskamp Institute has indicated it intends to submit an analysis of the outcomes for publication.
Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "ePage: 1 2 3 4 Related medicine technology :1
. Boston Scientific Supports Asthma Awareness Month With Donation to Asthma Foundation2
. Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle3
. Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death4
. Boston Scientific Offers New CRT-D Warranty Program Covering Phrenic Nerve Stimulation5
. Boston Scientifics SpyGlass® Direct Visualization System Achieves Global Utilization Milestones6
. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 20117
. Boston Scientific Announces CE Mark Approval and First Use of Blazer™ Open-Irrigated Catheter in Europe8
. Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions9
. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session10
. Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System11
. Boston Scientific Announces Results for First Quarter Ended March 31, 2011